Therapeutics & Vaccines
Engineered Botulinum Neurotoxin C1 With Selective Substrate Specificity
WARF: P100145US02
Inventors: Meyer Jackson, Dongsheng Wang
The Invention
An isolated polypeptide comprising a botulinum neurotoxin C1 light chain having a modified amino acid sequence relative to the sequence of a wild-type botulinum neurotoxin C1 light chain is disclosed. The modified botulinum neurotoxin C1 light chain is capable of selectively cleaving syntaxin protein, but has substantially reduced or no activity against SNAP-25 as compared to wild type botulinum neurotoxin C1 light chain, and is thus useful as a research tool and in medical treatment.
Tech Fields
For current licensing status, please contact Andy DeTienne at [javascript protected email address] or 608-960-9857